• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Johnson & Johnson

    1/24/24 12:51:33 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email
    SC 13G 1 s13g_011924-kenvue.htm SCHWEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No.   )1
     
     
    Kenvue Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.01 per share
    (Title of Class of Securities)
     
    49177J102
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ] Rule 13d-1(b)

     

    [ ] Rule 13d-1(c)

     

    [X] Rule 13d-1(d)

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     
     

     


    CUSIP No. 49177J102
    Page 2

     

     

    1.

    NAME OF REPORTING PERSON

     

    Johnson & Johnson

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [ ]

    (b)       [ ]

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New Jersey

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER 182,329,550
    6. SHARED VOTING POWER -0-
    7. SOLE DISPOSITIVE POWER 182,329,550
    8. SHARED DISPOSITIVE POWER -0-
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 182,329,550
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.5% (1)
    12. TYPE OF REPORTING PERSON CO
             

     

    (1) Based on 1,914,995,085 shares of Common Stock outstanding as of October 27, 2023, as reported in the Issuer’s Report on Form 10-Q for the period ended October 1, 2023 filed with the Securities and Exchange Commission on November 3, 2023.

     

     

     

     
     

     


    CUSIP No. 49177J102
    Page 3

     

     

    SCHEDULE 13G

     

    ITEM 1(a) NAME OF ISSUER:
       
      Kenvue Inc.
       
    ITEM 1(b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
      199 Grandview Road, Skillman, NJ  08558
       
    ITEM 2(a) NAME OF PERSON FILING:
       
      Johnson & Johnson
       
    ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE:
       
      One Johnson & Johnson Plaza, New Brunswick, NJ 08933
       
    ITEM 2(c) CITIZENSHIP:
       
      New Jersey
       
    ITEM 2(d) TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.01 per share (“Common Stock”)
       
    ITEM 2(e) CUSIP NUMBER:  
       
      49177J102
       
    ITEM 3 STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C):
       
      Not applicable.
       
    ITEM 4 OWNERSHIP:
       
      The information set forth in the cover page of this Schedule 13G is incorporated herein by reference.
       

     

     

     

     
     

     


    CUSIP No. 49177J102
    Page 4

     

     

    ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.
       
    ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      Not applicable.
       
    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:
       
      Not applicable.

     

    ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.
       
    ITEM 9 NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.
       
    ITEM 10 CERTIFICATION:
       
      Not applicable.

     

     

     

     
     

     


    CUSIP No. 49177J102
    Page 5

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: January 24, 2024

     

     

    JOHNSON & JOHNSON

     

      By: /s/ Marc Larkins
      Name: Marc Larkins
      Title: Secretary
         

     

     

     

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    5/13/2026$265.00Market Perform → Outperform
    Leerink Partners
    4/8/2026$250.00Buy
    TD Cowen
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    11/13/2025$230.00Sector Outperform
    Scotiabank
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    7/23/2025Hold → Buy
    Erste Group
    More analyst ratings

    $JNJ
    SEC Filings

    View All

    Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    7/15/26 7:49:04 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Johnson & Johnson

    11-K - JOHNSON & JOHNSON (0000200406) (Filer)

    6/25/26 5:15:53 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Johnson & Johnson

    11-K - JOHNSON & JOHNSON (0000200406) (Filer)

    6/25/26 5:13:18 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief TO and Risk Officer Wengel Kathryn E exercised 10,000 shares at a strike of $115.67 and sold $2,411,500 worth of shares (10,000 units at $241.15) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    6/12/26 5:23:31 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Woods Eugene A.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    6/11/26 4:56:44 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 134% to 24,911 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    5/4/26 4:58:59 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Johnson & Johnson from Market Perform to Outperform and set a new price target of $265.00

    5/13/26 7:59:34 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen resumed coverage on Johnson & Johnson with a new price target

    TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00

    4/8/26 8:36:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00

    1/28/26 7:11:28 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

    New branded recognition will spotlight the care, innovation and grit of U.S. healthcare professionals making a meaningful difference for patients, colleagues and communities. The collaboration will recognize healthcare leaders helping strengthen care amid growing pressure on health systems. Nominations will open on July 16, 2026 and close at 5:00 p.m. ET on August 28, 2026. Johnson & Johnson (NYSE:JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change t

    7/16/26 8:11:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DePuy Synthes Acquires Expanding Innovations™

    Transaction will bring expandable interbody cage solutions to DePuy Synthes' Spine portfolio to strengthen position across the lumbar fusion market DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment. Expanding Innovations (EI) is a commercial-stage medical technology company focused on developing and commercializing expandable implant technologies for spine surgery. Their proprietary, non-screw-b

    7/16/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026. The ex-dividend date is August 25, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

    7/15/26 6:25:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

    Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph J. Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430443361/en/Ryan Koors, Vice President, Investor Relations, Johnson & Johnson, effective May 7, 2026. "Ryan's appointment underscores the deep bench of financial talent within Johnson & Johnson and our commitm

    4/30/26 8:02:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    1/30/24 12:46:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Financials

    Live finance-specific insights

    View All

    DePuy Synthes Acquires Expanding Innovations™

    Transaction will bring expandable interbody cage solutions to DePuy Synthes' Spine portfolio to strengthen position across the lumbar fusion market DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment. Expanding Innovations (EI) is a commercial-stage medical technology company focused on developing and commercializing expandable implant technologies for spine surgery. Their proprietary, non-screw-b

    7/16/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026. The ex-dividend date is August 25, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

    7/15/26 6:25:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

    2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%* and adjusted operational growth of 5.7%* 2026 Second-Quarter earnings per share (EPS) of $2.27 and adjusted EPS* of $2.90 Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13 to $11.68 or 8.2% at the midpoint. The adjusted operational EPS* is increasing by $0.18 to $11.58 or 7.3% at the midpoint Advancing significant innovation for patients with approvals of TREMFYA to inhibit the progression of structural joint damage in adults with activ

    7/15/26 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care